Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Stocks in this Quantisnow insightHealth Care
Historical context for WHWK
Across the 20 sessions after earlier WHWK headlines, the stock closed higher 8 times and lower 12 times, with a median move of 3.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | WHWK | SPY |
|---|---|---|---|
| May 29, 2026 | Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference | -1.3% | +0.2% |
| May 22, 2026 | Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload | +4.4% | +0.4% |
| May 20, 2026 | Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit | +3.7% | +1.0% |
| May 15, 2026 | Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum | -7.8% | -1.2% |
| May 13, 2026 | Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing | +25.8% | +0.6% |
| May 7, 2026 | Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights | -5.1% | -0.3% |
Quantisnow market dataNASDAQ
WHWK
Whitehawk Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for WHWK
Full WHWK profile on Quantisnow Follow WHWK and get a push notification the moment its next story breaks.